Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Gemcitabine, Erlotinib, and Oxaliplatin in Pancreatic Cancer
NCT01531712Phase 2Terminated
- Sponsor
- Institut Català d'Oncologia
- Start
- Feb 2011
- Primary completion
- Dec 2012
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of erlotinib, oxaliplatin, gemcitabine in pancreatic adenocarcinoma (PDAC), sponsored by Institut Català d'Oncologia. Started Feb 2011; status: terminated.
02
Drugs
erlotiniboxaliplatingemcitabine
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT01531712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01531712.